Novartis, a Swiss pharmaceutical company, is to excel in the clinical trial data transparency domain, additional steps to be taken to extend its leadership. Since 2005, the company is voluntarily disclosing summaries of clinical study reports of its innovative medicines on its own website.
In addition, Novartis is committed to enhancing clinical study report summaries for all new pivotal studies to include easy-to-understand consumer language summaries and additional interpretation of data.
Novartis was the first company that supported data transparency from very long time and it was the first company publishing both positive and negative results of its innovative medicines within one year of the study completion.
Till date, the firm has registered 2,720 trials on ClinicalTrials.gov and published 559 trial results on the same site as well as 1,777 clinical study summaries.
Researchers can also now request access to patient level data on newly approved innovative medicines in 2014 through the same Idea Point portal as other pharmaceutical companies.
"Novartis has taken action to extend our leadership regarding clinical data transparency and access to data by researchers. This is designed to further advance science and innovation which can benefit patients," said Tim Wright, global head of development, Novartis Pharmaceuticals.
"We also believe that patient rights and privacy remain paramount, and recognize that such data should not be released without the express consent of the patient," Wright said.
By Ruchi Singh
In addition, Novartis is committed to enhancing clinical study report summaries for all new pivotal studies to include easy-to-understand consumer language summaries and additional interpretation of data.
Novartis was the first company that supported data transparency from very long time and it was the first company publishing both positive and negative results of its innovative medicines within one year of the study completion.
Till date, the firm has registered 2,720 trials on ClinicalTrials.gov and published 559 trial results on the same site as well as 1,777 clinical study summaries.
Researchers can also now request access to patient level data on newly approved innovative medicines in 2014 through the same Idea Point portal as other pharmaceutical companies.
"Novartis has taken action to extend our leadership regarding clinical data transparency and access to data by researchers. This is designed to further advance science and innovation which can benefit patients," said Tim Wright, global head of development, Novartis Pharmaceuticals.
"We also believe that patient rights and privacy remain paramount, and recognize that such data should not be released without the express consent of the patient," Wright said.
By Ruchi Singh
Copyright ⓒ Aju Press All rights reserved.